Dashboard
Manage Tickers

FATE


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

alibaba-to-rally-over-13-here-are-10-top-analyst-forecasts-for-thursday
Alibaba To Rally Over 13%? Here Are 10 Top...
05/16/2024 12:20:20

hc-wainwright--co-maintains-neutral-on-fate-therapeutics-lowers-price-target-to-5
HC Wainwright & Co. Maintains Neutral on F...
05/16/2024 11:39:37

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Fate Therapeutics (NASDAQ:FATE) with a Neutral and lowers the p...

canaccord-genuity-maintains-buy-on-fate-therapeutics-lowers-price-target-to-9
Canaccord Genuity Maintains Buy on Fate Th...
05/10/2024 18:37:42

Canaccord Genuity analyst Bill Maughan maintains Fate Therapeutics (NASDAQ:FATE) with a Buy and lowers the price target from...

bmo-capital-maintains-market-perform-on-fate-therapeutics-lowers-price-target-to-6
BMO Capital Maintains Market Perform on Fa...
05/10/2024 15:16:19

BMO Capital analyst Etzer Darout maintains Fate Therapeutics (NASDAQ:FATE) with a Market Perform and lowers the price target...

wedbush-maintains-neutral-on-fate-therapeutics-lowers-price-target-to-5
Wedbush Maintains Neutral on Fate Therapeu...
05/10/2024 13:38:07

Wedbush analyst David Nierengarten maintains Fate Therapeutics (NASDAQ:FATE) with a Neutral and lowers the price target from...

piper-sandler-maintains-neutral-on-fate-therapeutics-lowers-price-target-to-4
Piper Sandler Maintains Neutral on Fate Th...
05/10/2024 13:18:21

Piper Sandler analyst Edward Tenthoff maintains Fate Therapeutics (NASDAQ:FATE) with a Neutral and lowers the price target f...

fate-therapeutics-q1-2024-gaap-eps-047-inline-sales-1925m-beat-1114m-estimate
Fate Therapeutics Q1 2024 GAAP EPS $(0.47)...
05/09/2024 20:05:49

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.47) per share which met the analyst consensus estimate. This i...

fate-therapeutics-treats-first-lupus-patient-in-phase-1-study-of-ft819-car-t-cell-therapy
Fate Therapeutics Treats First Lupus Patie...
05/09/2024 12:33:33

forecasting-the-future-8-analyst-projections-for-fate-therapeutics
Forecasting The Future: 8 Analyst Projecti...
05/06/2024 16:00:41

wedbush-reiterates-neutral-on-fate-therapeutics-maintains-7-price-target
Wedbush Reiterates Neutral on Fate Therape...
05/06/2024 12:23:57

Wedbush analyst David Nierengarten reiterates Fate Therapeutics (NASDAQ:FATE) with a Neutral and maintains $7 price target.

fate-therapeutics-announces-presentation-of-ft522-preclinical-data-for-autoimmune-diseases-in-late-breaking-abstract-at-asgct-annual-meeting-adr-technology-incorporated-into-ft522-induces-functional-persistence-and-eliminates-alloreactive-host-immune-cells-in-sle-donor-pbmcs
Fate Therapeutics Announces Presentation O...
05/03/2024 20:31:26

Off-the-shelf, CD19-targeted CAR NK Cell Product Candidate Drives Rapid and Deep Depletion of SLE Donor CD19+ B cells ADR Techn...

wedbush-reiterates-neutral-on-fate-therapeutics-maintains-7-price-target
Wedbush Reiterates Neutral on Fate Therape...
04/23/2024 17:12:50

Wedbush analyst David Nierengarten reiterates Fate Therapeutics (NASDAQ:FATE) with a Neutral and maintains $7 price target.

fate-therapeutics-to-present-ft819-proof-of-concept-data-for-b-cell-mediated-autoimmune-diseases-at-asgct-annual-meeting
Fate Therapeutics To Present FT819 Proof-O...
04/22/2024 20:35:00

Key Therapeutic Mechanisms of Clinical Activity for Autoimmune Diseases, including B cell Depletion, Tissue Infiltration and Im...

where-fate-therapeutics-stands-with-analysts
Where Fate Therapeutics Stands With Analysts
04/11/2024 14:00:17

needham-reiterates-hold-on-fate-therapeutics
Needham Reiterates Hold on Fate Therapeutics
04/11/2024 10:09:37

Needham analyst Gil Blum reiterates Fate Therapeutics (NASDAQ:FATE) with a Hold.

12-health-care-stocks-moving-in-wednesdays-after-market-session
12 Health Care Stocks Moving In Wednesday'...
04/10/2024 20:31:09

b-of-a-securities-maintains-underperform-on-fate-therapeutics-raises-price-target-to-6
B of A Securities Maintains Underperform o...
03/28/2024 18:13:21

B of A Securities analyst Tazeen Ahmad maintains Fate Therapeutics (NASDAQ:FATE) with a Underperform and raises the price ta...

fate-therapeutics-announces-pricing-of-100m-underwritten-offering-and-concurrent-private-placement
Fate Therapeutics Announces Pricing Of $10...
03/19/2024 12:45:53

evaluating-fate-therapeutics-insights-from-5-financial-analysts
Evaluating Fate Therapeutics: Insights Fro...
03/19/2024 12:00:21

hc-wainwright--co-reiterates-neutral-on-fate-therapeutics-maintains-7-price-target
HC Wainwright & Co. Reiterates Neutral on ...
03/19/2024 10:53:43

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fate Therapeutics (NASDAQ:FATE) with a Neutral and maintains $...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION